We have found a concordant relationship between lower promoter methylation and higher gene expression levels for Pyroxd2 and Ptgfrn from the malignancy signature, which was also associated with the poorest survival in melanoma patients (Fig. 7). This evidence concerns the gene PYROXD2 and melanoma.